Gossamer Stock Analysis

GOSS
 Stock
  

USD 13.75  0.09  0.65%   

The latest price spike of Gossamer Bio may raise some interest from retail investors. The stock closed today at a share price of 13.75 on 655,100 in trading volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.96. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Gossamer Bio partners.
Please check Risk vs Return Analysis.
  
The Gossamer Bio stock analysis report makes it easy to digest most publicly released information about Gossamer Bio and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Gossamer Stock analysis module also helps to analyze the Gossamer Bio price relationship with some important fundamental indicators such as market cap and management efficiency.

Gossamer Stock Analysis Notes

About 90.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.26. Gossamer Bio had not issued any dividends in recent years. Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. Gossamer Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 185 people. To learn more about Gossamer Bio call Sheila Gujrathi at 858 684-1300 or check out www.gossamerbio.com.

Gossamer Bio Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Gossamer Bio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Gossamer Bio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Gossamer Bio is way too risky over 90 days horizon
Gossamer Bio appears to be risky and price may revert if volatility continues
Net Loss for the year was (234.15 M).
Gossamer Bio currently holds about 271.62 M in cash with (183.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.64.
Gossamer Bio has a frail financial position based on the latest SEC disclosures
Over 90.0% of the company shares are owned by institutional investors

Gossamer Bio Upcoming and Recent Events

Earnings reports are used by Gossamer Bio to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Gossamer Bio previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Gossamer Largest EPS Surprises

Earnings surprises can significantly impact Gossamer Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-02-25
2020-12-31-0.79-0.88-0.0911 
2019-11-12
2019-09-30-0.69-0.8-0.1115 
2020-08-11
2020-06-30-0.86-1-0.1416 
View All Earnings Estimates

Gossamer Bio SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Gossamer Bio prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Gossamer Bio investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Gossamer Bio specific information freely available to individual and institutional investors to make a timely investment decision.
9th of August 2022
Results of Operations and Financial Condition
View
13th of July 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
10th of June 2022
Submission of Matters to a Vote of Security Holders
View
10th of May 2022
Results of Operations and Financial Condition
View
25th of April 2022
Other Events. Results of Operations and Financial Condition
View
3rd of March 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
10th of February 2022
Unclassified Corporate Event
View
3rd of February 2022
Unclassified Corporate Event
View

Gossamer Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.06 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Gossamer Bio's market, we take the total number of its shares issued and multiply it by Gossamer Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Gossamer Profitablity

Gossamer Bio's profitability indicators refer to fundamental financial ratios that showcase Gossamer Bio's ability to generate income relative to its revenue or operating costs. If, let's say, Gossamer Bio is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Gossamer Bio's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Gossamer Bio's profitability requires more research than a typical breakdown of Gossamer Bio's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.57) (0.62) 
Return on Average Equity(1.19) (1.22) 
Return on Invested Capital(0.81) (0.87) 

Management Efficiency

The entity has return on total asset (ROA) of (34.55) % which means that it has lost $34.55 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (154.94) %, meaning that it created substantial loss on money invested by shareholders. Gossamer Bio management efficiency ratios could be used to measure how well gossamer bio manages its routine affairs as well as how well it operates its assets and liabilities. As of 08/18/2022, Return on Average Assets is likely to drop to -0.62. In addition to that, Return on Average Equity is likely to drop to -1.22. Gossamer Bio Assets Non Current are relatively stable at the moment as compared to the past year. Gossamer Bio reported last year Assets Non Current of 11.88 Million. As of 08/18/2022, Total Assets Per Share is likely to grow to 5.79, while Current Assets are likely to drop slightly above 319 M.
Last ReportedProjected for 2022
Book Value per Share 1.62  1.75 
Enterprise Value over EBIT(4.00) (4.32) 
Enterprise Value over EBITDA(3.98) (4.29) 
Price to Book Value 7.12  6.13 
Tangible Assets Book Value per Share 4.59  4.71 
Enterprise Value832.6 M750.3 M
Tangible Asset Value343.7 M330.4 M

Technical Drivers

As of the 18th of August 2022, Gossamer Bio retains the Downside Deviation of 4.17, risk adjusted performance of 0.1901, and Market Risk Adjusted Performance of 0.8135. Gossamer Bio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Gossamer Bio, which can be compared to its competitors. Please check out Gossamer Bio variance and potential upside to decide if Gossamer Bio is priced fairly, providing market reflects its last-minute price of 13.75 per share. Given that Gossamer Bio has jensen alpha of 0.7777, we strongly advise you to confirm Gossamer Bio's regular market performance to make sure the company can sustain itself at a future point.

Gossamer Bio Price Movement Analysis

The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Triangular Moving Average shows Gossamer Bio double smoothed mean price over a specified number of previous prices (i.e., averaged twice).
.

Gossamer Bio Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gossamer Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gossamer Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gossamer Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Gossamer Bio Predictive Daily Indicators

Gossamer Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Gossamer Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Gossamer Bio Forecast Models

Gossamer Bio time-series forecasting models is one of many Gossamer Bio's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Gossamer Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Gossamer Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Gossamer Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Gossamer shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Gossamer Bio. By using and applying Gossamer Stock analysis, traders can create a robust methodology for identifying Gossamer entry and exit points for their positions.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. Gossamer Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 185 people.

Current Gossamer Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Gossamer analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Gossamer analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
21.67Strong Buy6Odds
Gossamer Bio current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Gossamer analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Gossamer stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Gossamer Bio, talking to its executives and customers, or listening to Gossamer conference calls.
Gossamer Analyst Advice Details

Gossamer Stock Analysis Indicators

Gossamer Bio stock analysis indicators help investors evaluate how Gossamer Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Gossamer Bio shares will generate the highest return on investment. By understating and applying Gossamer Bio stock analysis, traders can identify Gossamer Bio position entry and exit signals to maximize returns.
Quick Ratio7.86
Fifty Two Week Low5.64
Shares Short Prior Month12.09M
Average Daily Volume Last 10 Day1.39M
Average Daily Volume In Three Month1.36M
Shares Percent Shares Out17.52%
Short Percent Of Float20.94%
Forward Price Earnings-5.76
Float Shares58.64M
Fifty Two Week High14.30
Enterprise Value To Ebitda-3.76
Fifty Day Average9.32
Two Hundred Day Average9.68
Please check Risk vs Return Analysis. Note that the Gossamer Bio information on this page should be used as a complementary analysis to other Gossamer Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Gossamer Stock analysis

When running Gossamer Bio price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Is Gossamer Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gossamer Bio. If investors know Gossamer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gossamer Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
1.3 B
Return On Assets
-0.39
Return On Equity
-2.26
The market value of Gossamer Bio is measured differently than its book value, which is the value of Gossamer that is recorded on the company's balance sheet. Investors also form their own opinion of Gossamer Bio's value that differs from its market value or its book value, called intrinsic value, which is Gossamer Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gossamer Bio's market value can be influenced by many factors that don't directly affect Gossamer Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gossamer Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Gossamer Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gossamer Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.